KOBE, Japan, March 27, 2016 /PRNewswire/ -- Sysmex Corporation (HQ: Kobe, Japan) and Clearbridge BioMedics (HQ: Singapore) have partnered to develop a new liquid biopsy system through a joint development collaboration.
The development of the new system will leverage upon the microfluidics and cell separation technologies of Clearbridge BioMedics. The collaboration will combine Sysmex's global leadership in haematology diagnostics and expertise in developing liquid biopsy assays with Clearbridge BioMedics' in-depth domain knowledge in microfluidics for the enrichment of rare cells, which could potentially lead to a new product line to complement Sysmex's current suite of best-in-class haematology analysers.
"Liquid biopsy and cancer diagnostics is an important focus area for Sysmex. Clearbridge BioMedics has demonstrated their unique and versatile cell separation technologies. We look forward to working together again and further innovating through our Sysmex Open Innovation Lab platform, which aims to encourage open innovation through global collaborations," said Mr Kaoru Asano, Member of the Sysmex Managing Board and Senior Executive Officer, Managing Director and Head of Research and Technology Development.
"We are excited to be partnering with Sysmex Corporation, a global leading healthcare company. This collaboration follows on from our working relationships over the last few years, where we both evaluated our technologies and respective intellectual properties, and have concluded there is considerable synergies. We are pleased to be in this partnership and bring it to the next level," said Mr Johnson Chen, Managing Director and Founder Clearbridge BioMedics.
About Clearbridge BioMedics
Clearbridge BioMedics is a clinical stage oncology research and diagnostics company that enables real-time liquid biopsy using a label-free Circulating Tumour Cell (CTC) enrichment platform. It is a National University of Singapore (NUS) / Singapore-MIT Alliance for Research and Technology (SMART) spin-off company that is committed to revolutionizing cancer diagnostics and patient care. The ClearCell® FX1 System, using the CTChip®, is based on novel microfluidics technology that effectively isolates intact and live, viable CTCs from patients' blood. The system uses inertial focusing microfluidics for label-free CTC enrichment, capturing heterogeneous and dynamic cancer cells that could be used for cancer screening, diagnosis, staging, personalised medicine and treatment monitoring. The system allows for real time analysis of disease before, during, and after treatment, which has become increasingly critical in the new era of precision medicine and immunotherapy.
Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America. The company has won numerous awards and garnered global recognition for the ClearCell® FX System. Clearbridge BioMedics has attained ISO 13485 certification in 2011.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 40 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R & D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, China and Asia Pacific and employs more than 7,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange. For more information about Sysmex Corporation and its affiliate companies, please visit http://www.sysmex.co.jp/en/.
Media enquiries can be directed to:
Chan Yiu Lin (Ms)
Greener Grass Communications
SOURCE Clearbridge BioMedics